Archford Capital Strategies LLC Has $3.52 Million Position in Merck & Co., Inc. $MRK

Archford Capital Strategies LLC lessened its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 20.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 27,354 shares of the company's stock after selling 6,991 shares during the period. Archford Capital Strategies LLC's holdings in Merck & Co., Inc. were worth $3,515,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Kingdom Financial Group LLC. acquired a new position in Merck & Co., Inc. in the fourth quarter worth about $25,000. Abound Financial LLC bought a new position in shares of Merck & Co., Inc. during the 4th quarter worth approximately $26,000. Prosperity Bancshares Inc acquired a new stake in Merck & Co., Inc. in the 4th quarter valued at $26,000. High Note Wealth LLC boosted its stake in Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company's stock valued at $31,000 after buying an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. bought a new stake in Merck & Co., Inc. in the fourth quarter valued at $31,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrades support valuation: Leerink Partners raised its price target from $127 to $161 and maintained an “outperform” rating, while Guggenheim increased its target from $146 to $170 and assigned a “buy” rating. The revisions suggest analysts see further upside from Merck’s commercial execution and pipeline. Benzinga analyst rating reports
• Positive Sentiment: Pipeline expansion addresses the Keytruda patent cliff: Merck is pairing antibody-drug conjugates (ADCs) with Keytruda in women’s cancers, seeking to improve outcomes in difficult-to-treat tumors while building future revenue sources before Keytruda faces patent pressure. Merck pairs ADCs with Keytruda in women’s cancer push
• Neutral Sentiment: Investor attention is focused on management commentary: Merck presented at the Wells Fargo 21st Annual Healthcare Conference and is scheduled to participate in Morgan Stanley’s global healthcare conference. These events may provide additional detail on Keytruda demand, pipeline progress and long-term growth plans. Wells Fargo healthcare conference transcript
• Neutral Sentiment: Keytruda and new products remain central to the bull case: Commentary highlights Keytruda’s current growth contribution and Merck’s efforts to develop products capable of extending momentum beyond the anticipated 2028 patent cliff. MRK’s strong recent performance and elevated valuation leave expectations high. Merck trading near 52-week high
• Negative Sentiment: Long-term patent risk remains: Investors are watching whether Merck can replace revenue that may be lost when Keytruda’s exclusivity weakens. The company’s ability to commercialize ADC combinations and other pipeline assets is therefore critical to sustaining growth and its current valuation. Merck outlook and GARDASIL commentary

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Barclays increased their price objective on Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 29th. Morgan Stanley raised shares of Merck & Co., Inc. from an "equal weight" rating to an "overweight" rating and upped their target price for the stock from $116.00 to $179.00 in a report on Thursday, August 20th. Wall Street Zen upgraded shares of Merck & Co., Inc. from a "hold" rating to a "buy" rating in a research report on Saturday, August 22nd. Bank of America lifted their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a "buy" rating in a report on Tuesday, June 30th. Finally, Wolfe Research raised their price objective on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the stock an "outperform" rating in a report on Tuesday, August 25th. Sixteen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $150.33.

Insider Transactions at Merck & Co., Inc.

In related news, EVP Richard R. Deluca sold 11,699 shares of the business's stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $131.63, for a total transaction of $1,539,939.37. Following the completion of the sale, the executive vice president directly owned 110,167 shares of the company's stock, valued at $14,501,282.21. The trade was a 9.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP David R. Maraldo sold 18,706 shares of the business's stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the sale, the executive vice president directly owned 18,212 shares of the company's stock, valued at approximately $2,344,248.64. This trade represents a 50.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is currently owned by insiders.

Merck & Co., Inc. Price Performance

Merck & Co., Inc. stock opened at $147.69 on Thursday. The business's fifty day moving average is $135.91 and its two-hundred day moving average is $124.10. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The firm has a market cap of $364.37 billion, a P/E ratio of 118.15, a P/E/G ratio of 6.46 and a beta of 0.21. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $156.92.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The firm's quarterly revenue was up 5.1% compared to the same quarter last year. During the same period last year, the company posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities research analysts forecast that Merck & Co., Inc. will post 2.76 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.3%. Merck & Co., Inc.'s dividend payout ratio (DPR) is currently 272.00%.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck's pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.